Guangzhou Lays Out Biopharma Welcome Mat In Investment Push
This article was originally published in PharmAsia News
Guangzhou is planning to deepen investment in the biopharmaceutical industry and to formulate preferential policies and incentives to encourage tie-ups with multinational pharma firms. The provincial capital aims to develop the industry as a pillar sector that will contribute 15% of its GDP by 2025.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.